JP2007504213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504213A5 JP2007504213A5 JP2006525215A JP2006525215A JP2007504213A5 JP 2007504213 A5 JP2007504213 A5 JP 2007504213A5 JP 2006525215 A JP2006525215 A JP 2006525215A JP 2006525215 A JP2006525215 A JP 2006525215A JP 2007504213 A5 JP2007504213 A5 JP 2007504213A5
- Authority
- JP
- Japan
- Prior art keywords
- glutaminyl
- use according
- pharmaceutically acceptable
- acceptable salt
- thiazolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 glutaminyl thiazolidine Chemical compound 0.000 claims 9
- FAAZAHIRCXGFFM-ZETCQYMHSA-N (4s)-4-amino-5-oxo-5-pyrrolidin-1-ylpentanamide Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCCC1 FAAZAHIRCXGFFM-ZETCQYMHSA-N 0.000 claims 8
- 239000003472 antidiabetic agent Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229940125708 antidiabetic agent Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- WQIRZULZPQRECJ-GSTITVNRSA-N (4s)-4-amino-5-oxo-5-(1,3-thiazolidin-2-yl)pentanamide;hydrochloride Chemical compound Cl.NC(=O)CC[C@H](N)C(=O)C1NCCS1 WQIRZULZPQRECJ-GSTITVNRSA-N 0.000 claims 4
- 229940122355 Insulin sensitizer Drugs 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229960003105 metformin Drugs 0.000 claims 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 3
- 229940123208 Biguanide Drugs 0.000 claims 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 229940122199 Insulin secretagogue Drugs 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 229960002632 acarbose Drugs 0.000 claims 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims 1
- 229960001466 acetohexamide Drugs 0.000 claims 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 229960004111 buformin Drugs 0.000 claims 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims 1
- 229960001761 chlorpropamide Drugs 0.000 claims 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 1
- 229950009226 ciglitazone Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950000269 emiglitate Drugs 0.000 claims 1
- 229950002375 englitazone Drugs 0.000 claims 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- 229960001764 glibornuride Drugs 0.000 claims 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 claims 1
- 229960000346 gliclazide Drugs 0.000 claims 1
- 229960004346 glimepiride Drugs 0.000 claims 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 claims 1
- 229950005319 glisolamide Drugs 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- 229960001110 miglitol Drugs 0.000 claims 1
- 229960003243 phenformin Drugs 0.000 claims 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229960002277 tolazamide Drugs 0.000 claims 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims 1
- 229960005371 tolbutamide Drugs 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical group C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960001729 voglibose Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49953503P | 2003-09-02 | 2003-09-02 | |
| PCT/IB2004/003082 WO2005020983A2 (en) | 2003-09-02 | 2004-09-02 | Combination therapy for glycaemic control |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504213A JP2007504213A (ja) | 2007-03-01 |
| JP2007504213A5 true JP2007504213A5 (enExample) | 2007-08-30 |
Family
ID=34272835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525215A Withdrawn JP2007504213A (ja) | 2003-09-02 | 2004-09-02 | 糖血症コントロールの処置のための併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060287251A1 (enExample) |
| EP (1) | EP1663200A2 (enExample) |
| JP (1) | JP2007504213A (enExample) |
| KR (1) | KR20060119927A (enExample) |
| CN (1) | CN1845731A (enExample) |
| AU (1) | AU2004267955A1 (enExample) |
| BR (1) | BRPI0413204A (enExample) |
| CA (1) | CA2536432A1 (enExample) |
| EA (1) | EA200600356A1 (enExample) |
| IL (1) | IL173844A0 (enExample) |
| MX (1) | MXPA06002127A (enExample) |
| NO (1) | NO20061085L (enExample) |
| WO (1) | WO2005020983A2 (enExample) |
| ZA (1) | ZA200601770B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
| GB0623892D0 (en) * | 2006-11-29 | 2007-01-10 | Medical Res Council Technology | Assay |
| CN102933598A (zh) * | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| CA2851690C (en) * | 2011-10-28 | 2022-07-26 | Sanofi-Aventis Deutschland Gmbh | Treatment protocol of diabetes type 2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE29924609U1 (de) * | 1999-05-28 | 2004-04-22 | Probiodrug Ag | Neue Effektoren von Dipeptidylpeptidase IV |
| US20030139434A1 (en) * | 2000-01-21 | 2003-07-24 | Bork Balkan | Combinations comprising dipeptidylpeptidase-iv inhibitor |
| US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| JP2005527504A (ja) * | 2002-02-28 | 2005-09-15 | プロシディオン・リミテッド | グルタミニルを基礎するｄｐｉｖ阻害剤 |
| EP1543023B1 (en) * | 2002-09-18 | 2010-03-17 | Prosidion Limited | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
-
2004
- 2004-09-02 JP JP2006525215A patent/JP2007504213A/ja not_active Withdrawn
- 2004-09-02 WO PCT/IB2004/003082 patent/WO2005020983A2/en not_active Ceased
- 2004-09-02 BR BRPI0413204-1A patent/BRPI0413204A/pt not_active IP Right Cessation
- 2004-09-02 EP EP04769446A patent/EP1663200A2/en not_active Withdrawn
- 2004-09-02 AU AU2004267955A patent/AU2004267955A1/en not_active Abandoned
- 2004-09-02 US US10/570,113 patent/US20060287251A1/en not_active Abandoned
- 2004-09-02 EA EA200600356A patent/EA200600356A1/ru unknown
- 2004-09-02 MX MXPA06002127A patent/MXPA06002127A/es not_active Application Discontinuation
- 2004-09-02 KR KR1020067004354A patent/KR20060119927A/ko not_active Withdrawn
- 2004-09-02 CN CNA2004800251945A patent/CN1845731A/zh active Pending
- 2004-09-02 CA CA002536432A patent/CA2536432A1/en not_active Abandoned
-
2006
- 2006-02-21 IL IL173844A patent/IL173844A0/en unknown
- 2006-02-28 ZA ZA200601770A patent/ZA200601770B/en unknown
- 2006-03-06 NO NO20061085A patent/NO20061085L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI241185B (en) | Antidiabetic formulation | |
| TWI280125B (en) | Pharmaceutical compositions for treating type 2 diabetes in drug naive human patients | |
| KR100643833B1 (ko) | 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물 | |
| JP2016501841A5 (enExample) | ||
| ES2311530T3 (es) | Combinaciones farmaceuticas para el tratamiento y la prevencion de la diabetes mellitus. | |
| JP2008517921A5 (enExample) | ||
| JP2006515267A5 (enExample) | ||
| US6780432B1 (en) | Core formulation | |
| TW202015683A (zh) | Glp1r激動劑的治療用途 | |
| JP2008517921A (ja) | Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤 | |
| WO2007035665A1 (en) | Use of a dpp-iv inhibitor to reduce hypoglycemic events | |
| US6296874B1 (en) | Core formulation comprising troglitazone and abiguanide | |
| Kiayias et al. | Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients | |
| JP2007504213A5 (enExample) | ||
| US20030224046A1 (en) | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent | |
| US6461639B2 (en) | Core formulation | |
| RU2012147449A (ru) | Способы использования диацереина в дополнительном лечении диабета | |
| Luna et al. | The use of insulin secretagogues in the treatment of type 2 diabetes | |
| MXPA06001629A (es) | Composicion nueva que comprende rosiglitazona y otro agente antidiabetico. | |
| AU2001257456B2 (en) | A core formulation | |
| JPWO2020194046A5 (enExample) | ||
| TR201802120T4 (en) | A PHARMACEUTICAL COMPOSITION INCLUDING A COMPOUND INCLUDING DIPPEPIDYL PEPTIDASE-IV ACTIVITY AND OTHER ANTIDIABETIC OR ANTIOBETICITY AGENTS AS PROTECTIVE SUBSTANCES FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY. | |
| MXPA04000180A (es) | Formulacion de nucleo que comprende hidrocloruro de pioglitazona y una biguanida. | |
| JP2004536841A (ja) | コア製剤 | |
| AU2001257456A1 (en) | A core formulation |